Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacterium Infantis

Also known as: Bifidobacterium infantis, B. infantis, Bifidobacterium longum subsp. infantis

Overview

Bifidobacterium infantis is a probiotic bacteria species naturally inhabiting the human gut, especially prevalent in infants. It's distinguished by its ability to metabolize human milk oligosaccharides (HMOs), making it particularly beneficial for infant gut health and development. As a probiotic, B. infantis contributes to a balanced gut microbiota, which is crucial for immune function and overall well-being. Primary applications include improving gut health, alleviating symptoms of irritable bowel syndrome (IBS), and exploring potential neuroprotective effects. It is available in various forms, including capsules, powders, and as part of probiotic blends. Research on B. infantis is ongoing, with a growing body of evidence supporting its benefits, especially in preterm infants and individuals with IBS. Its role in modulating the gut-brain axis is also an area of increasing interest.

Benefits

Bifidobacterium infantis offers several evidence-based benefits, particularly for specific populations. In preterm infants, supplementation with B. infantis reduces the risk of necrotizing enterocolitis (NEC), late-onset sepsis (LOS), and overall mortality. A systematic review indicated that probiotics containing B. infantis were more effective in reducing NEC incidence compared to those without it (RR: 0.38 vs. 0.67, p = 0.01). For individuals with IBS, composite probiotics that include B. infantis may alleviate symptoms such as abdominal pain and bloating, although the efficacy of single-strain B. infantis is less clear. Emerging research also suggests potential neuroprotective effects in animal models of neurodegenerative diseases, though human evidence remains limited. These benefits highlight the clinical relevance of B. infantis in promoting gut health and potentially influencing neurological well-being.

How it works

Bifidobacterium infantis primarily works by colonizing the gut and modulating the gut microbiota composition. Its unique ability to utilize human milk oligosaccharides (HMOs) promotes the growth of beneficial bacteria, fostering a healthy gut environment. B. infantis interacts with the gastrointestinal system, influencing gut barrier function and immune response. Additionally, it may affect the central nervous system via the gut-brain axis, potentially influencing neurological health. While specific molecular targets are not fully defined, the probiotic's mechanism likely involves modulating the immune system and reducing inflammation within the gut.

Side effects

Bifidobacterium infantis is generally considered safe for most individuals, including healthy adults and preterm infants, when used as directed. Common side effects are typically mild and gastrointestinal in nature, such as bloating or gas. Uncommon or rare side effects are not consistently reported, though there is a theoretical risk of infection in severely immunocompromised individuals. There are no well-documented drug interactions associated with B. infantis. However, individuals with compromised immune systems should consult with a healthcare provider before using B. infantis or any probiotic supplement. Preterm infants may benefit from B. infantis supplementation under medical supervision to monitor for any adverse reactions.

Dosage

The optimal dosage of Bifidobacterium infantis varies depending on the specific product, the intended use, and the individual's health status. Typically, probiotic supplements containing B. infantis provide dosages ranging from 10^8 to 10^9 CFU (colony-forming units) per serving. It is often recommended to take B. infantis with food to enhance its survival through the stomach acid and improve colonization in the gut. While a maximum safe dose has not been definitively established, it is generally considered safe within typical probiotic dosage ranges. Capsules and powders are common forms of B. infantis supplements. Always follow the manufacturer's instructions and consult with a healthcare provider for personalized dosage recommendations.

FAQs

Is Bifidobacterium infantis safe?

Generally, yes. However, immunocompromised individuals should consult a healthcare provider before use.

When is the best time to take Bifidobacterium infantis?

It is best taken with meals to enhance survival through the stomach acid and improve gut colonization.

What results can I expect from taking Bifidobacterium infantis?

Results vary based on the condition being treated, but it may help with gut health and IBS symptoms.

Is Bifidobacterium infantis a cure-all?

No, it is not a cure-all. Its benefits are condition-specific and may not be universal.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/37460707/ – This systematic review and meta-analysis of 14,606 preterm infants found that probiotics containing Bifidobacterium infantis significantly reduced the incidence of necrotizing enterocolitis (NEC) compared to probiotics without it. The study highlights the importance of B. infantis in promoting gut health and reducing mortality in preterm infants, suggesting its inclusion in probiotic supplementation protocols.
https://pubmed.ncbi.nlm.nih.gov/28166427/ – This meta-analysis examined five studies involving IBS patients and found that composite probiotics containing Bifidobacterium infantis may alleviate IBS symptoms. While the findings suggest a potential benefit, the study notes that the efficacy of single-strain B. infantis remains unclear, indicating the need for further research to determine the specific role of B. infantis in IBS management.
https://www.mdpi.com/2072-6643/17/3/391 – This systematic review explores the potential neuroprotective effects of Bifidobacterium infantis in neurodegenerative diseases, drawing from both animal and human studies. The review suggests that B. infantis may offer neuroprotective benefits, but emphasizes the need for more clinical trials to confirm these findings and fully understand the mechanisms involved in humans.
https://downloads.aap.org/AAP/PDF/2023-12%20SONPM%20Articles%20of%20Interest%20DEC.pdf – This article highlights the benefits of Bifidobacterium infantis in preterm infants, emphasizing its role in reducing the risk of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS). It underscores the importance of using probiotics containing B. infantis as part of a comprehensive strategy to improve outcomes for vulnerable preterm infants.
https://www.researchgate.net/publication/372431390_Bifidobacterium_infantis_as_a_probiotic_in_preterm_infants_a_systematic_review_and_meta-analysis – This systematic review and meta-analysis focuses on the use of Bifidobacterium infantis as a probiotic in preterm infants. The study provides evidence supporting the effectiveness of B. infantis in reducing the incidence of NEC and improving overall health outcomes in this population, reinforcing its clinical significance in neonatal care.